

**Bilal Ahmad Rah (Ph. D.)**  
**Postdoctoral Research Associate**

Iron Biology Group,  
Sharjah Institute of Medical Research,  
University of Sharjah, Sharjah, United Arab Emirates  
Phone No.: +91-8825067653; +971-508696592  
Email ID: [bilalrah09@gmail.com](mailto:bilalrah09@gmail.com), [brah@sharjah.ac.ae](mailto:brah@sharjah.ac.ae)  
Web: [https://scholar.google.co.in/citations?user=Ey0Y2\\_AAAAAJ&hl=en](https://scholar.google.co.in/citations?user=Ey0Y2_AAAAAJ&hl=en)  
[https://www.researchgate.net/profile/Bilal\\_Rah](https://www.researchgate.net/profile/Bilal_Rah)  
<https://www.ncbi.nlm.nih.gov/pubmed/?term=bilal+rah>

---

**Education**

- 2003-2005      **B. Sc. (Medical Laboratory Technology)**, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India.
- 2006-2008      **M. Sc. (Biochemistry)** University of Kashmir, Jammu and Kashmir, India.
- 2011-2016      **Ph. D. (Biochemistry/Cancer Biology)**, Indian Institute of Integrative Medicine-Council of Scientific and Industrial Research (IIIM-CSIR), Academy of Scientific and Innovative Research (AcSIR), New Delhi, India.

**Work Experience**

- 2022-present      **Postdoctoral Research Associate**, Sharjah Institute of Medical Research (SIMR), University of Sharjah, Sharjah, UAE.
- 2021-2022      **Senior Resident/Demonstrator**, Advanced Center for Human Genetics (ACHG), Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, India.
- 2019-2020      **Post-doctoral Research Associate**, Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Burraidah, Saudi Arabia
- 2017-2019      **Senior Resident/Demonstrator**, Department of Immunology and Molecular Medicine, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, India.
- 2017-2017      **Postdoctoral Research Associate**, Department of Pathology and Genetics, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
- 2016-2017      **Research Associate**, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center (UNMC), Omaha, NE, USA.

**Research Skills**

**Cell culture technique:**

- Isolation of genomic plasmid/DNA/RNA, RT/q-RT-PCR,

- Electrophoretic mobility shift assay (EMSA),
- Cell proliferation and viability assays, invasion and motility assays, scratch assays,
- Gelatin zymography,
- Immunocytochemistry, immunohistochemistry.
- Confocal and laser scan microscopy,
- Flow cytometry (FACS) analysis, ELISA,

**Molecular Diagnostics:**

- For *Mycobacterium Tuberculosis*, *Duchenne Muscular Dystrophy (mutational profile)*, Myeloproliferative Neoplasm (*JAK-2 mutation*), *Cystic Fibrosis (CFTR mutation profile)*, and mutational profile for chronic pancreatitis

**Animal handling:**

- Mouse Genotyping,
- Handling transgenic mouse models (VPS-34<sup>-/-</sup> model to study autophagy in gut, Claudin-2<sup>-/-</sup> and Claudin-3<sup>-/-</sup> mice models),
- Orthotopic and subcutaneous xenograft mouse models
- Murine tumor models (Ehrlich Ascites Carcinoma, Sarcoma-180, L1210-Lymphoblastic Leukemia and p388-Leukemic Murine Models) for in-vivo anticancer studies

**Recombinant DNA technology:**

- Gene cloning, bacterial culture and preparation of competent cells,
- Gene knockdown using siRNA/shRNA technology.

**Protein technology:**

- Recombinant protein expression,
- Western Blotting,
- Immunoprecipitation for protein-protein interactions,
- Chromatin immunoprecipitation (CHIP) for DNA-protein interaction.

**Professional Memberships and other experience**

2020	Reviewer for the journal Frontiers in Oncology
2020	Reviewer for the journal Archives of Medical Sciences
2020	Reviewer for the Journal of Toxicology reports
2020	Reviewer for American Journal of Translational Research
2018	Life member of Indian Association of Immunological Society
2017	Co-Editor of Intechopen book entitled “Cancer Survivorship” and “Breast Cancer Biology”
2011	Member, Indian Association for Cancer Research (IACR).
2014	Editorial board member of the Journal “Advances in Biomedicine and Pharmacy”
2016	Board Member of SERB to review the project submitted for funding to Science and Research Engineering Board (SERB) formerly known

as Department of Science and Technology (DST), in India.

### **Honors and Awards**

- 2008 Awarded **National Eligibility Test** (NET) Jointly Conducted by Council of Scientific and Industrial Research (CSIR) and University of Grants Commission (UGC) –India
- 2010 Awarded **Graduate Aptitude Test for Engineering** (GATE), India
- 2015 Awarded Best Paper in Cancer Pharmacology Division, Indian Institute of Integrative Medicine. (**Autophagy. 2015;11(2):314-31. doi: 10.1080/15548627.2015.1017182.**)
- 2015 Awarded Best Paper in Medicinal Chemistry Division, Indian Institute of Integrative Medicine. (**J Med Chem. 2015 Apr 23;58(8):3432-44. doi: 10.1021/jm501942m.**)
- 2020 450 plus google citations with h-index and h10-index equal to 12 and 14 respectively.

### **Mentoring of Doctorate / Graduate / Undergraduate / Summer Students / Medical Fellows**

- 2011 Inderpal Singh (M.Sc. student from SMVDU, J&K, India)
- 2012 Debasis Nayak (M. Pharama student from NIPER, UP, India)
- 2012-2016 Debasis Nayak (Ph.D. Candidate, Cancer Pharmacology Division, IIIM)
- 2013-2016 Reyaz ur Rasool (Ph.D. Candidate, Cancer Pharmacology Division, IIIM)
- 2017-2018 Arjumand Wani (M.Sc. student from Kashmir University, J&K, India)
- 2017-2018 Nahidah Shah (M.Sc. student, Dept. of Immu. and Mol. Med. SKIMS)
- 2017-2020 Iqra Beigh (Ph.D. Candidate, Dept. of Immu. and Mol. Med. SKIMS)
- 2017-2021 Tahira Yousuf (Ph.D. Candidate, Dept. of Immu. and Mol. Med. SKIMS)
- 2017-2020 Bilal Ahmad Wani (Ph.D. Candidate, Dept. of Med. Micro. Amity University)
- 2018 Amina Jan (M.Sc. student from Kashmir University, J&K, India)
- 2018 Tanzilla (M.Sc. student from Kashmir University, J&K, India)
- 2018 Adnan (DMLT student from Ramzana Para-Medical College, J&K, India)
- 2018-2022 Muzamil Farooq ((Ph.D. Candidate, Dept. of Immu. and Mol. Med. SKIMS)
- 2018-2022 Ifra Mushtaq (Ph.D. Candidate, Dept. of Immu. and Mol. Med. SKIMS)
- 2021 Uroos Ali (M.Sc. student from Central University, Srinagar,

- 2021 J&K, India)  
Ayman Kar (M.Sc. student from Central University, Srinagar,  
J&K, India)
- 2021 Ubaidah (M.Sc. student from Central University, Srinagar,  
J&K, India)

### **Peer-reviewed Publications & book chapters**

<b>Publications</b>	<b>37</b>
<b>Google citations</b>	<b>770</b>
<b>h-index</b>	<b>17</b>
<b>i10-index</b>	<b>22</b>
<b>Total Impact Factor</b>	<b>185</b>
<b>Book chapters</b>	<b>02</b>

37. Alnuqaydan AM, Almutary AG, A Alsahli M, Alnasser S, ***Rah B\****. *Tamarix articulata* Induced Prevention of Hepatotoxicity Effects of In Vivo Carbon Tetrachloride by Modulating Pro-Inflammatory Serum and Antioxidant Enzymes to Reverse the Liver Fibrosis. ***Antioxidants (Basel)***. 2022 Sep 15;11(9):1824. doi: 10.3390/antiox11091824. PMID: 36139897; PMCID: PMC9496017. (**\* Corresponding author**) (**IF: 7.675**) (**Q1**)
36. Bhat GR, Sethi I, ***Rah B***, Kumar R, Afroze D. Innovative *in Silico* Approaches for Characterization of Genes and Proteins. ***Front Genet.*** 2022 May 18;13:865182. doi: 10.3389/fgene.2022.865182. PMID: 35664302; PMCID: PMC9159363. (**IF: 4.771**)
35. Nazeer NU, Bhat MA, ***Rah B***, Bhat GR, Wani SI, Yousuf A, Dar AM, Afroze D. Mutational Assessment in NKX2-5 and ACTC1 Genes in Patients with Congenital Cardiac Septal Defect (CCSD) from Ethnic Kashmiri Population. ***Int. J. Environ. Res. Public Health.*** 2022,19,9884. <http://doi.org/10.3390/ijerph19169884>. (**IF: 4.614**)

34. Mushtaq I, Bhat GR, **Rah B**, Besina S, Zahoor S, Wani MA, Shah MA, Bashir S, Farooq M, Rather RA, Afroze D. Telomere Attrition With Concomitant hTERT Overexpression Involved in the Progression of Gastric Cancer May Have Prognostic and Clinical Implications in High-Risk Population Group From North India. **Front Oncol.** 2022 Jul 13;12:919351. doi: 10.3389/fonc.2022.919351. PMID: 35912187; PMCID: PMC9326504. **(IF: 5.738) (Q1)**
33. Alnuqaydan AM, Almutary A, Bhat GR, Mir TA, Wani SI, Rather MY, Mir SA, Alshehri B, Alnasser S, Ali Zainy FM, **Rah B\***. Evaluation of the Cytotoxic, Anti-Inflammatory, and Immunomodulatory Effects of Withaferin A (WA) against Lipopolysaccharide (LPS)-Induced Inflammation in Immune Cells Derived from BALB/c Mice. **Pharmaceutics.** 2022 Jun 13;14(6):1256. doi: 10.3390/pharmaceutics14061256. PMID: 35745829; PMCID: PMC9229769. **(\* Corresponding author) (IF: 6.525) (Q1)**
32. **Rah B**, Rather RA, Bhat GR, Baba AB, Mushtaq I, Farooq M, Yousuf T, Dar SB, Parveen S, Hassan R, Mohammad F, Qassim I, Bhat A, Ali S, Zargar MH, Afroze D. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. **Front Pharmacol.** 2022 Mar 24;13:821344. doi: 10.3389/fphar.2022.821344. PMID: 35401182; PMCID: PMC8987160. **(IF: 5.988) (Q1)**
31. Baba AB, **Rah B**, Bhat GR, Mushtaq I, Parveen S, Hassan R, Hameed Zargar M, Afroze D. Transforming Growth Factor-Beta (TGF- $\beta$ ) Signaling in Cancer-A Betrayal Within. **Front Pharmacol.** 2022 Feb 28;13:791272. doi: 10.3389/fphar.2022.791272. PMID: 35295334; PMCID: PMC8918694. **(IF: 5.988) (Q1)**
30. Abdullah M. Alnuqaydan, Abdulmajeed G. Almutary, Ohoud Y. Alshehri, Hanan Ali Henidi, Abdullah M. Alajlan, Abdullah Al Tamim, Abdullah Alowaifeer, Mohd Younis Rather, **Bilal Rah\***. Evaluation of the cytotoxic activity of *Tamarix articulata* and its anticancer potential in prostate cancer cells. **Journal of Applied Pharmaceutical Sciences.** 2022;12(02):089-108 **(\* Corresponding author) (IF: 1.376)**
29. **Rah B**, Banday MA, Bhat GR, Shah OJ, Jeelani H, Kawoosa F, Yousuf T, Afroze D. Evaluation of biomarkers, genetic mutations, and epigenetic modifications in early diagnosis of pancreatic cancer. *World J Gastroenterol.* 2021 Sep 28;27(36):6093-6109. doi: 10.3748/wjg.v27.i36.6093. PMID: 34629822; PMCID: PMC8476336. **World Journal of Gastroenterology (IF: 5.374) (Q1)**

28. Allemailem KS, Almatroudi A, Alrumaihi F, Almansour NM, Aldakheel FM, Rather RA, Afroze D, **Rah B\***. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. *American Journal of Translational Research*, 2021;13(4):3868-3889. (IF: 3.940) (Q1) (\* Corresponding author)
27. Alnuqaydan AM, **Rah B#\***. Tamarix articulata inhibits cell proliferation, promotes cell-death mechanisms and triggers G0/G1 cell cycle arrest in hepatocellular carcinoma cells. *Food Technology and Biotechnology*; 59(2) (2021) (IF: 2.33) (Q2) (# equal contribution, \* Corresponding author)
26. Jan I, Rather RA, Mushtaq I, Malik AA, Besina S, Baba AB, Farooq M, Yousuf T, **Rah B**, Afroze D. Helicobacter pylori subdues cytokine signaling to alter mucosal inflammation via hypermethylation of suppressor of cytokine signaling 1 (SOCS1) gene during gastric carcinogenesis". *Frontiers in Oncology-Molecular and Cellular Oncology* 2020; (IF: 5.738) (Q1)
25. Dar MI, Khajuria A, Dar K, **Rah B**, Sidiq T, Ganie S, Masood A, Amin S. In vitro and in vivo Immunomodulatory Effect of Lavatera cashmeriana Protein Concentrate. *Indian J Pharm Sci.* 2020;82(3):483-91. (IF: 0.975) (Q3)
24. Alnuqaydan AM, **Rah B#\***. Comparative assessment of biological activities of different parts of halophytic plant Tamarix articulata (T. articulata) growing in Saudi Arabia. *Saudi Journal of Biological Sciences.* 2020 Oct 1;27(10):2586-92. (IF: 4.052) (Q1) (# equal contribution, \* Corresponding author)
23. Alnuqaydan AM, **Rah B#\***, Almutary AG, Chauhan SS. Synergistic antitumor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells. *American Journal of Cancer Research.* 2020;10(3):799. (IF: 5.942) (Q1) (# equal contribution, \* Corresponding author)
22. Alnuqaydan AM, **Rah B**. Tamarix articulata (T. articulata)-an important halophytic medicinal plant with potential pharmacological properties. *Current pharmaceutical biotechnology.* 2019 Mar 1;20(4):285-92. (IF: 2.829) (Q2)
21. Rasool I, Wani KA, Yousuf A, Bhat IA, **Rah B**, Nazir SU, Hussain S, Dubey S. Role of the functional polymorphism of survivin gene (-31G/C) and risk of breast cancer in a North Indian population. *Clinical Breast Cancer.* 2018 Aug 1;18(4):e671-6. (IF: 3.078) (Q2)

20. Dar AM, **Rah B\***, Mir S, Nabi R, Gatoo MA, Mashrai A, Khan Y. DNA binding, artificial nuclease activity and cytotoxic studies of newly synthesized steroidal pyrimidines. *International journal of biological macromolecules*. 2018 May 1;111:52-61. (IF: 8.025) (Q1) (\*Corresponding author)
19. Mubashir K, Ganai BA, Ghazanfar K, Akbar S, **Rah B**, Tantry M, Masood A. Anti-inflammatory and immuno-modulatory studies on LC-MS characterised methanol extract of *Gentiana kurroo* Royle. *BMC complementary and alternative medicine*. 2017 Dec;17(1):78. (IF: 4.782) (Q1)
18. Rather SA, Shah AM, Ali SA, Dar RA, **Rah B**, Ali A, Hassan QP. Isolation and characterization of *Streptomyces tauricus* from Thajiwas glacier—a new source of actinomycin-D. *Medicinal Chemistry Research*. 2017 Sep 1;26(9):1897-902. (IF: 2.351) (Q2)
17. Ahmad R, **Rah B**, Bastola D, Dhawan P, Singh AB. Obesity-induces organ and tissue specific tight junction restructuring and barrier deregulation by claudin switching. *Scientific reports*. 2017 Jul 11;7(1):1-6. (IF: 4.996) (Q1)
16. Nayak D, Kumar A, Chakraborty S, ur Rasool R, Amin H, Katoch A, Gopinath V, Mahajan V, Zilla MK, **Rah B**, Gandhi SG. Inhibition of Twist1-mediated invasion by Chk2 promotes premature senescence in p53-defective cancer cells. *Cell Death & Differentiation*. 2017 Jul;24(7):1275-87. (IF: 12.067) (Q1)
15. Rasool RU, Nayak D, Chakraborty S, Faheem MM, **Rah B**, Mahajan P, Gopinath V, Katoch A, Iqra Z, Yousuf SK, Mukherjee D. AKT is indispensable for coordinating Par-4/JNK cross talk in p21 downmodulation during ER stress. *Oncogenesis*. 2017 May;6(5):e341-e341. (IF: 6.524) (Q1)
14. **Rah B**, Nayak D, Rasool R, Chakraborty S, Katoch A, Amin H, Goswami A. Reprogramming of molecular switching events in UPR driven ER stress: scope for development of anticancer therapeutics. *Current molecular medicine*. 2016 Sep 1;16(8):690-701. (IF: 2.616) (Q2)
13. Chakraborty S, ur Rasool R, Kumar S, Nayak D, **Rah B**, Katoch A, Amin H, Ali A, Goswami A. Cristacarpin promotes ER stress-mediated ROS generation leading to premature senescence by activation of p21 waf-1. *Age*. 2016 Jun;38(3):1-4. (IF: 4.648) (Q1)
12. Ur Rasool R, **Rah B**, Amin H, Nayak D, Chakraborty S, Rawoof A, Mintoo MJ, Yousuf K, Mukherjee D, Kumar LD, Mondhe DM. Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: a novel c-FLIP inhibitory

- mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E. **Scientific reports**. 2016 Jan 5;6:18800. **(IF: 4.996) (Q1)**
11. Nayak D, Amin H, **Rah B**, Ur Rasool R, Sharma D, Gupta AP, Kushwaha M, Mukherjee D, Goswami A. A therapeutically relevant, 3, 3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78 kDa (GRP78). **Chemico-Biological Interactions**. 2015 May 5;232:58-67. **(IF: 5.168) (Q1)**
  10. **Rah B**<sup>#</sup>, Ur Rehman S, Lone SH, Rasool RU, Farooq S, Nayak D, Chikan NA, Chakraborty S, Behl A, Mondhe DM, Goswami A, Bhat KA. Design and synthesis of antitumor heck-coupled Sclareol analogues: modulation of BH3 family members by SS-12 in autophagy and apoptotic cell death. **Journal of Medicinal Chemistry**. 2015 Apr 23;58(8):3432-44. **(IF: 8.039) (Q1) (# equal contribution)**
  09. **Rah B**, Rasool RU, Nayak D, Yousuf SK, Mukherjee D, Kumar LD, Goswami A. PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells. **Autophagy**. 2015 Feb 1;11(2):314-31. **(IF: 13.391) (Q1)**
  08. Haris M, Mahmood R, Rahman H, **Rah B**, Nazneen. Inhibition of wound closure and decreased colony formation by Clerodendrum infortunatum L. in lung cancer cell line. **Int J Curr Res Biosci Plant Biol**. 2015;2(9):66-73. **(IF: 2.99)**
  07. Zilla MK, Nayak D, Amin H, Nalli Y, **Rah B**, Chakraborty S, Kitchlu S, Goswami A, Ali A. 4'-Demethyl-deoxypodophyllotoxin glucoside isolated from Podophyllum hexandrum exhibits potential anticancer activities by altering Chk-2 signaling pathway in MCF-7 breast cancer cells. **Chemico-biological interactions**. 2014 Dec 5;224:100-7. **(IF: 5.168) (Q1)**
  06. Sinha S, Mishra P, Amin H, **Rah B**, Nayak D, Goswami A, Kumar N, Vishwakarma R, Ghosal S. A new cytotoxic quinolone alkaloid and a pentacyclic steroidal glycoside from the stem bark of Crataeva nurvala: Study of anti-proliferative and apoptosis inducing property. **European journal of medicinal chemistry**. 2013 Feb 1;60:490-6. **(IF: 7.088) (Q1)**
  05. Singh I, Amin H, **Rah B**, Goswami A. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer. **Front Biosci (Schol Ed)**. 2013 Jan 1;5:231-46. **(IF: 2.214) (Q2)**
  04. Rather SA, Kumar S, **Rah B**, Arif M, Ali A, Qazi P. A potent cytotoxic metabolite from terrestrial actinomycete, Streptomyces collinus. **Medicinal Chemistry Research**. 2014 Jan 1;23(1):382-7. **(IF: 2.351) (Q2)**



03. Chanda D, Bhushan S, Guru SK, Shanker K, Wani ZA, **Rah B**, Luqman S, Mondhe DM, Pal A, Negi AS. Anticancer activity, toxicity and pharmacokinetic profile of an indanone derivative. **European journal of pharmaceutical sciences**. 2012 Dec 18;47(5):988-95. (IF: 5.112) (Q2)
02. **Rah B**, Amin H, Yousuf K, Khan S, Jamwal G, Mukherjee D, Goswami A. A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. **PloS one**. 2012 Sep 4;7(9):e44039. (IF: 3.752) (Q2)
01. Sharma DK, **Rah B**, Lambu MR, Hussain A, Yousuf SK, Tripathi AK, Singh B, Jamwal G, Ahmed Z, Chauria N, Nargotra A. Design and synthesis of novel N, N'-glycoside derivatives of 3, 3'-diindolylmethanes as potential antiproliferative agents. **MedChemComm**. 2012;3(9):1082-91. (IF: 5.121) (Q3)

#### **Book Chapter (02)**

1. **Rah B**, Ali S, Dar MI, Afroze D. Breast cancer: management and survivorship. *Cancer Survivorship*. 2019 Jan 3:16-37. **Publisher; Intechopen.com books**
2. Ali S, Afroze D, **Rah B**, Iqbal K. Immunomodulating agents in the treatment of acute myeloid leukemia: A combinatorial immunotherapeutic approach, **Publisher Bentham Sciences (Anticancer Agents), Pp. 1-22(22), DOI: 10.2174/9789811478437121060003**

#### **Papers presented in Conferences/Seminars/Symposiums**

##### **a) International Conference Proceedings**

1. Afroze D, **Rah B**, Farooq M. Complementing role of survivin and VEGF in the hypoxia mediated angiogenesis as putative therapeutics for breast cancer. Volume 49, Page number 305-306, Publisher Wiley, **European Journal of Immunology, 2019**.

##### **b) Oral Presentation**

1. **Rah B**, Singh AB, Afroze D. Obesity-induces Organ and Tissue Specific Tight Junction Restructuring and Barrier Deregulation by Claudin Switching. **7<sup>th</sup> Annual Conference of Indian Academy of Biomedical Sciences**, Department of Clinical Biochemistry, SKIMS, Srinagar, Kashmir, J&K, India.

### c) Poster Presentation

1. **Rah B**, Singh AB, Afroze D. Obesity Induces Mucosal Leakiness by modulating specific Tight Junction Protein Expression and Function. **45<sup>th</sup> Annual Meeting of Indian Immunology Society (Immunocon-2018)**
2. **Rah B**, Ur-Rasool R, Nayak D, Yousuf K, Mukherjee D, Kumar LD, Goswami A. PAWR-mediated Suppression of BCL2 Promotes Switching of 3-azido-witaferin A (3-AWA)-induced Autophagy to Apoptosis in Prostate Cancer Cells. **Cellular and Molecular Mechanisms of Disease Processes**, University of Kashmir, Srinagar, J&K, India.
3. Ur Rasool R, **Rah B**, Nayak D, Amin H, Goswami A. Controlling Protein Translational Machinery in Prostate Cancer Cells. **5<sup>th</sup> International Conference on Translational Cancer Research Multi-Targeted Approach to Treatment of Cancer**, New Delhi, India.
4. **Rah B**, Raza M, Akram M, Sharma PR, Goswami A. Par-4 as a Therapeutic Target in the Endoplasmic Reticulum (ER) Stress Pathways. **30<sup>th</sup> Annual Convention of Indian Association for Cancer Research and International Symposium on Signaling Network and Cancer**, IICB, Kolkata, India.